PriceTargets.com logo

Immunic - IMUX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.20
  • Forecasted Upside: 1,089.19%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 2 Strong Buy Ratings
$1.11 As of 04/25/2025 05:00 PM ET
▼ -0.03 (-2.63%)

This chart shows the closing price for IMUX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Immunic Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMUX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMUX

Analyst Price Target is $13.20
▲ +1,089.19% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Immunic in the last 3 months. The average price target is $13.20, with a high forecast of $28.00 and a low forecast of $5.00. The average price target represents a 1,089.19% upside from the last price of $1.11.

This chart shows the closing price for IMUX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in Immunic. This rating has held steady since October 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2024
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2024
  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2025
  • 2 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2025
  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2025

Latest Recommendations

  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/16/2025B. RileyReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
4/15/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/10/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
4/1/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
3/25/2025William BlairInitiated CoverageOutperform
2/26/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
2/21/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
2/20/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
1/7/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
11/25/2024HC WainwrightInitiated CoverageBuy$10.00
9/16/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
9/9/2024Leerink PartnrsUpgradeStrong-Buy
9/9/2024Leerink PartnersReiterated RatingOutperform$5.00
8/27/2024B. RileyInitiated CoverageBuy$6.00
7/16/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$28.00 ➝ $28.00
4/5/2024Brookline Capital ManagementReiterated RatingBuy$10.00
11/14/2023WedbushReiterated RatingOutperform$7.00
10/10/2023WedbushBoost TargetOutperform ➝ Outperform$5.00 ➝ $7.00
8/4/2023WedbushReiterated RatingOutperform$5.00
7/27/2023WedbushReiterated RatingOutperform ➝ Outperform$5.00
1/31/2023WedbushReiterated RatingOutperform$5.00
10/21/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$9.00 ➝ $5.00
9/21/2022WedbushReiterated RatingOutperform$11.00
9/19/2022HC WainwrightReiterated RatingBuy$26.00
8/8/2022AegisLower TargetBuy$40.00 ➝ $35.00
6/3/2022Leerink PartnersLower TargetOutperform$45.00 ➝ $9.00
6/2/2022WedbushLower Target$61.00 ➝ $14.00
5/17/2022Piper SandlerLower TargetOverweight$71.00 ➝ $39.00
5/6/2022WedbushReiterated RatingOutperform
2/26/2022WedbushReiterated RatingBuy$61.00
12/20/2021HC WainwrightReiterated RatingBuy$25.00
12/16/2021WedbushReiterated RatingOutperform$61.00
10/15/2021WedbushReiterated RatingBuy$61.00
9/7/2021HC WainwrightLower TargetBuy$40.00 ➝ $25.00
8/9/2021WedbushLower TargetOutperform$68.00 ➝ $61.00
7/14/2021HC WainwrightReiterated RatingBuy$40.00
7/2/2021WedbushReiterated RatingBuy$68.00
7/2/2021HC WainwrightReiterated RatingBuy$40.00
5/7/2021JMP SecuritiesReiterated RatingOutperform$55.00 ➝ $56.00
4/16/2021WedbushReiterated RatingBuy$72.00
4/15/2021AegisInitiated CoverageBuy$55.00
3/24/2021JMP SecuritiesInitiated CoverageOutperform$55.00
3/7/2021Leerink PartnersReiterated RatingBuy$45.00
2/18/2021Chardan CapitalReiterated RatingBuy
10/2/2020Leerink PartnersInitiated CoverageOutperform$45.00
9/14/2020HC WainwrightReiterated RatingBuy$56.00
8/25/2020Piper SandlerInitiated CoverageOverweight$71.00
8/21/2020HC WainwrightLower TargetBuy$60.00 ➝ $56.00
8/7/2020Roth CapitalInitiated CoverageBuy$64.00
8/6/2020LADENBURG THALM/SH SHBoost TargetBuy$50.00 ➝ $57.00
8/3/2020BMO Capital MarketsBoost TargetOutperform$40.00 ➝ $61.00
8/3/2020HC WainwrightBoost TargetPositive ➝ Buy$45.00 ➝ $60.00
7/27/2020WedbushReiterated RatingBuy$58.00
7/20/2020BMO Capital MarketsInitiated CoverageOutperform$40.00
7/12/2020WedbushReiterated RatingBuy$58.00
6/17/2020WedbushReiterated RatingBuy$58.00
6/16/2020HC WainwrightReiterated RatingBuy$45.00
6/9/2020HC WainwrightReiterated RatingBuy$45.00
6/4/2020WedbushInitiated CoverageOutperform$59.00
5/27/2020HC WainwrightReiterated RatingBuy
5/11/2020HC WainwrightInitiated CoverageBuy$45.00
(Data available from 4/25/2020 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2024
  • 9 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2024
  • 8 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2024
  • 7 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2025
  • 5 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2025
  • 5 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2025
  • 7 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2025

Current Sentiment

  • 7 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Immunic logo
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Read More

Today's Range

Now: $1.11
Low: $1.10
High: $1.22

50 Day Range

MA: $1.09
Low: $0.88
High: $1.26

52 Week Range

Now: $1.11
Low: $0.83
High: $2.11

Volume

422,903 shs

Average Volume

633,516 shs

Market Capitalization

$106.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91

Frequently Asked Questions

What sell-side analysts currently cover shares of Immunic?

The following Wall Street research analysts have issued reports on Immunic in the last twelve months: B. Riley, D. Boral Capital, EF Hutton Acquisition Co. I, HC Wainwright, Leerink Partners, Leerink Partnrs, Piper Sandler, StockNews.com, and William Blair.
View the latest analyst ratings for IMUX.

What is the current price target for Immunic?

0 Wall Street analysts have set twelve-month price targets for Immunic in the last year. Their average twelve-month price target is $13.20, suggesting a possible upside of 1,089.2%. Piper Sandler has the highest price target set, predicting IMUX will reach $28.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $5.00 for Immunic in the next year.
View the latest price targets for IMUX.

What is the current consensus analyst rating for Immunic?

Immunic currently has 6 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMUX will outperform the market and that investors should add to their positions of Immunic.
View the latest ratings for IMUX.

What other companies compete with Immunic?

Other companies that are similar to Immunic include Revance Therapeutics, Maze Therapeutics, Mereo BioPharma Group, Zhengye Biotechnology and Zevra Therapeutics. Learn More about companies similar to Immunic.

How do I contact Immunic's investor relations team?

Immunic's physical mailing address is 1200 AVENUE SUITE 200, NEW YORK NY, 10036. The company's listed phone number is (332) 255-9818 and its investor relations email address is [email protected]. The official website for Immunic is www.immunic-therapeutics.com. Learn More about contacing Immunic investor relations.